within Pharmacolibrary.Drugs.ATC.A;

model A03AD01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.1666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0015,
    k12             = 0.8,
    k21             = 0.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03AD01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Papaverine is an opium alkaloid antispasmodic drug used to relax smooth muscles, primarily for the treatment of visceral spasms, vasospasm, and occasionally for erectile dysfunction by intra-arterial administration. It is not commonly used today due to the availability of safer and more effective alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after intravenous and oral administration.</p><h4>References</h4><ol><li><p>Kraus, C, et al., &amp; Ritschel, WA (1991). Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs. <i>Biopharmaceutics &amp; drug disposition</i> 12(7) 537–546. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510120707&quot;>10.1002/bdd.2510120707</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1932615/&quot;>https://pubmed.ncbi.nlm.nih.gov/1932615</a></p></li><li><p>Ritschel, WA, &amp; Hammer, GV (1977). Pharmacokinetics of papaverine in man. <i>International journal of clinical pharmacology and biopharmacy</i> 15(5) 227–228. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/873666/&quot;>https://pubmed.ncbi.nlm.nih.gov/873666</a></p></li><li><p>Shaaya, AN, et al., &amp; Ritschel, WA (1992). Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs. <i>Methods and findings in experimental and clinical pharmacology</i> 14(5) 373–378. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1513193/&quot;>https://pubmed.ncbi.nlm.nih.gov/1513193</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03AD01;
